Description
Lactacystin is a proteasome inhibitor initially produced by Streptomyces that exhibits hepatoprotective, anti-metastatic, and anticancer chemotherapeutic activities. Lactacystin increases the Bax/Bcl-2 ratio and inhibits proliferation of cells and growth of tumors in models of glioma. Additionally, lactacystin inhibits growth and migration of smooth muscle cells. In animal models of intestinal ischemia/reperfusion-induced liver injury, lactacystin inhibits activation of NF-κB, suppresses infiltration of neutrophils, and decreases levels of ICAM-1.
References
Wang H, Zhang S, Zhong J, et al. The proteasome inhibitor lactacystin exerts its therapeutic effects on glioma via apoptosis: an in vitro and in vivo study. J Int Med Res. 2013 Feb;41(1):72-81. PMID: 23569132.
Barringhaus KG, Matsumura ME. The proteasome inhibitor lactacystin attenuates growth and migration of vascular smooth muscle cells and limits the response to arterial injury. Exp Clin Cardiol. 2007 Fall;12(3):119-24. PMID: 18650992.
Yao JH, Li YH, Wang ZZ, et al. Proteasome inhibitor lactacystin ablates liver injury induced by intestinal ischaemia-reperfusion. Clin Exp Pharmacol Physiol. 2007 Nov;34(11):1102-8. PMID: 17880361.
